Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

nt; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, VALSTAR(R) and SUPPRELIN(R)-LA; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, DELATESTRYL and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/17/2014)... , Sept. 17, 2014   GS1 US ... to implement GS1 Standards to support the 2013 ... patient safety and security in the pharmaceutical supply ... Standards to U.S. Pharmaceutical Supply Chain Business Processes ... , was developed in collaboration with GS1 ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
(Date:9/17/2014)... Sept. 17, 2014 Sutro Biopharma, a biopharmaceutical ... the biopharmaceutical division of Merck KGaA, Darmstadt, ... the United States and ... license agreement to develop antibody drug conjugates (ADCs). ADCs ... drug. The antibody is thought to specifically target and ...
Breaking Medicine Technology:New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... Nov. 2, 2010 GeNO LLC ( www.genollc.com ... announced today that it has submitted an Investigational ... and Drug Administration (FDA) for the GeNO NITROsyl ... pulmonary hypertension in patients with pulmonary arterial hypertension ...
... , a drug research and development company focused on the ... awarded a grant by the United States government under the ... of its lead product CM-AT for autism.  CM-AT is presently ... US. The QTDP grant program provides support for ...
Cached Medicine Technology:GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension 2GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension 3Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant 2
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... September 17, 2014 Boston Children’s ... create a monthly concert series, introducing young Museum ... the Top, America’s premier national platform celebrating the ... Many of the young musicians featured will also ... “Boston Children’s Museum is fortunate to partner with ...
(Date:9/17/2014)... 2014 Smart Flour Foods™ has been ... Grocer, a leading trade magazine targeted toward food retailers. ... and flavor, among other attributes. Smart Flour Foods’ Uncured ... in the September print issue of Progressive Grocer as ... pizza won based on its superior performance in the ...
(Date:9/17/2014)... Palo Alto, CA (PRWEB) September 17, 2014 ... with Stanford University, revealed 12 companies raising rounds of ... attended by a few hundred investors and media, was ... square foot headquarters located next to the university. The ... staff and volunteers, adjacent to StartX-QB3 Labs, a 2,000 ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2
... doing away with the user charges imposed on patients at ... senior CPI(M) MP said today. ,This was conveyed to ... Basudeb Acharia when they called on Prime Minister Manmohan Singh ... Nirmala Deshpande and Hannan Mollah, met the Prime Minister weeks ...
... next week to repair a tennis elbow injury that has ... African vice-captain was forced out of last year's tour of ... the tour of Sri Lanka in August., ,'However, he ... in India in September and the 2007 World Cup in ...
... Intelligence arrested three persons, including the Managing Director ... alleged illegal export of Ephedrine tablets, a controlled ... Substances (NDPS) Act, 1985. ,According to ... persons have been remanded to judicial custody by ...
... by the Johns Hopkins researchers it is found that ... brain which controls// the muscle movements is responsible for ... research is Professor Reza Shadmehr and he and his ... PLoS Biology. This study would help to change the ...
... Royal Brisbane and Women's Hospital (RBWH), Sydney struggles with ... in three wards were found with a bacterium ... skin. ,To prevent the spread, 12 patients ... cent burns) were shifted to Sydney hospital and some ...
... the city, joined by members of Medical Representatives Association ... protest the Centre's reservation// proposals, affecting heatlh services in ... a number of women and ayurvedic doctors, also took ... to Prime Minister Manmohan Singh to the Deputy Commissioner, ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: